Ultragenyx Pharmaceutical Inc.
RARE
$29.85
-$0.46-1.52%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 23.91% | -13.27% | 0.10% | -1.46% | 22.90% |
| Total Depreciation and Amortization | -4.13% | -0.98% | 3.68% | -1.18% | 0.19% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -38.37% | 46.24% | -18.13% | -8.43% | 8.42% |
| Change in Net Operating Assets | 61.48% | -348.93% | -26.20% | 88.46% | 129.20% |
| Cash from Operations | 34.96% | -109.39% | -18.67% | 12.95% | 59.65% |
| Capital Expenditure | -85.80% | -102.45% | 59.55% | 19.51% | 37.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -39.25% | 17.24% | 137.75% | -537.70% | -35.92% |
| Cash from Investing | -40.63% | 16.70% | 137.29% | -554.89% | -35.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 53,179.62% | -95.07% | -23.67% | -98.92% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.00% | 11,968.97% | 200.00% |
| Cash from Financing | 53,179.62% | -95.07% | -71.49% | -97.10% | 663,787.93% |
| Foreign Exchange rate Adjustments | 101.24% | 158.55% | -293.96% | 296.76% | 4.57% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 209.97% | -287.85% | 107.26% | -189.71% | 479.16% |